Generic drug market in Central Europe to develop by 3%-6% pa between 2016 and 2021

According to estimates from Poland-based market research group PMR presented in the report “Generic and innovative drugs in Central Europe 2016 - Development forecasts for 2016-2021,” Poland will be the most rapidly developing market in the area of generics in the next five years, given its traditionally unchangeable pro-generic policy and the generally attractive nature of the market, based on its affluence and size.

Romania’s growth potential is constrained by recent regulations

In the past years, the most substantial increases in the generic and innovative subgroups were recorded in Romania and Bulgaria. This is because these countries are, in general, the least developed (the least saturated) among those analyzed. At the other end of the scale were Poland and Hungary, as the governments in both countries implemented very severe cost-containment policies: the Reimbursement Act in Poland and the Szell Kalman Plan in Hungary. These were also harmful for the innovative drugs subgroup.